AUPH vs CUBE · P/E 28, rev $283.1M vs P/E 25, rev $1.07B
Aurinia Pharmaceuticals Inc (AUPH) versus CubeSmart (CUBE) — a side-by-side from cached financials, not a winner call.
Aurinia Pharmaceuticals Inc (AUPH) is a biotechnology company listed on US.
CubeSmart (CUBE) is a reit - industrial company listed on US.
Latest reported AUPH revenue for 2025-12-31 was $283.1M. Net income was $287.2M. Revenue was up 372.8% from 2024-12-31 to 2025-12-31. AUPH currently screens at market cap $1.03B and trailing P/E 28.1.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
AUPH currently screens at market cap $1.03B and trailing P/E 28.1. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
Not investment advice. Open the AUPH and CUBE stock pages for the full models.
Not investment advice.